Neuronetics, Inc. appointed Dan Reuvers as President and Chief Executive Officer, effective March 23, 2026, succeeding Keith Sullivan who stepped down on that date and retired on March 31, 2026 after five and a half years leading the company. Reuvers brings more than 30 years of medical device experience with a proven track record of growing revenue, earnings, and cash flow. Most recently, he served as President and CEO of Tactile Medical, where he grew revenue from $187 million to approximately $300 million while delivering record earnings and cash flow. Prior to Tactile Medical, Reuvers spent 12 years at Integra LifeSciences, rising to Executive Vice President and President of Codman Specialty Surgical, a 1 billion dollar global neurosurgery division. He also held leadership roles at Omni-Tract Surgical, Advanced Respiratory, Inc., and Vital Signs, Inc.
Company Leadership Transition
Chairman Rob Cascella stated that Reuvers is a proven public company CEO with extensive experience building and scaling medical technology businesses, with a strong track record in driving revenue growth, expanding market access, and successfully integrating acquisitions. Cascella praised outgoing CEO Sullivan for transforming Neuronetics from a single-product company into a vertically integrated mental health platform through the strategic acquisition of Greenbrook TMS, building a national clinic network, and significantly expanding insurance coverage and physician adoption of transcranial magnetic stimulation (TMS).
Reuvers said he is “honored and excited” to join Neuronetics, noting that the company has a “leading TMS treatment platform, in conjunction with our national care delivery network” and that millions of people suffering from depression remain underserved by existing treatments. The company’s NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (MDD) in adults, with over 8 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression. Through its Greenbrook division, Neuronetics offers both NeuroStar Advanced Therapy and SPRAVATO esketamine nasal spray, having provided more than 2 million treatments to over 60,000 patients struggling with depression.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110871904/Neuronetics-Appoints-Dan-Reuvers-As-President-And-Chief-Executive-Officer